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Oral hypoglycemic drugs now 
available are of two types. The 
biguanides, of which phenformin 
(DBI) is the only one available, in-
crease glucose utilization by mus-
cles. The sulfonylureas, tolbutamide 
( Orinase), acetohexamide (Dyme-
lor), and chlorpropamide (Diabi-
nese), stimulate the pancreas to 
produce and release more insulin. 
All three sulfonylureas have the 
same effect in responsive patients, 
but they differ in potency and in 
duration of action. 
THE SULFONYLUREAS 
Tolbutamide is rapidly metabo-
lized into an inactive chemical that 
is promptly excreted in the urine. 
Because the blood half-life is six 
hours, this drug should be given 
two to four times each day. On ces-
sation of treatment the hypogly-
cemic effect is promptly dissipated. 
Acetohexamide has a blood half-
life of six hours, but the metabolic 
product has hypoglycemic activity 
that lasts for several hours before it 
is excreted in the urine. In patients 
with poor renal function, the metab-
olite may accumulate in the blood 
and cause prolonged hypoglycemia 
after a small dose. This drug is usu-
ally given twice daily. 
Chlorpropamide is not metabo-
lized but is excreted in the urine 
over a period of four days. Because 
the blood half-life of this drug is 36 
hours, the entire daily dose can be 
given at breakfast. Since there are 
occas~onal reports of cholestatic 
jaundice after large doses, chlor-
. propamide should not be used in 
patients with known or suspected 
liver disease. 
Comparative studies of these three 
drugs shows that chlorpropamide 
has the greatest overall effectiveness 
with the best diabetic control, the 
smallest number of secondary fail-
ures, and the lowest cost to the pa-
tient. The difference between the 
three drugs is so small that each 
physician should routinely use only 
one but learn to use that one well. 
The sulfonylureas are most ef-
fective in patients who develop dia-
betes after the age of 30, who have 
few diabetic symptoms, and who 
are near normal weight. Younger 
patients and those who have keto-
nuria, weight loss, and the classical 
symptoms of diabetes usually re-
quire insulin. A few symptomatic 
patients who require insulin for ini-
tial control may later respond to a 
sulfonylurea. 
The sulfonylureas are usually of 
no value in juvenile patients. On 
rare occasions when diabetes was 
detected during the asymptomatic 
phase, it has been possible to achieve 
satisfactory control for several 
months with the sulfonylureas. Be-
cause this response is always tem-
porary, it is <essential that the pa-
tient be followed closely so that 
insulin may be started promptly 
when needed. 
FAILURES OF ORAL 
HYPOGLYCEMIC AGENTS 
"Primary failure" refers to lack 
of response to the oral agent from 
the beginning of therapy. "Second-
ary failure" describes the loss of 
MCV QUARTERLY 2(1): 32-34, 1966 
diabetic control after initial satis-
factory control for more than a 
month on an oral drug. The exact 
incidence of secondary failure will 
depend upon how freely the drug is 
used initially and how strict are the 
criteria of control. If the drug is 
used only in those patients expected 
to have an excellent diabetic re-
sponse, the incidence of primary 
and secondary failure will be low. 
If the drug is used in younger pa-
tients with moderately severe dia-
betes, there will be a higher inci-
dence of failures. Some patients 
classified as secondary failures ini-
tially were not under good control 
and should be classified as primary 
failures. Many obese patients fol-
low their diet initially, but later eat 
excessively, gain weight, develop 
hyperglycemia and are classified as 
a secondary failure. Some patients 
develop poor control during a tran-
sient period of stress and must be 
changed to insulin. If the sulfonyl-
urea is continued with supple-
mental insulin during the period of 
stress, the oral drug may later be 
successful. In our series, the clinic 
patients who had a fasting blood 
sugar over 200 mg per 100 ml after 
being on the maximum dose of the 
drug for one week were classified 
as secondary failures. The highest 
incidence of failure is in the first 
few months, but true secondary fail-
ure may develop after several years 
of excellent diabetic control. A pa-
tient who is under excellent control 
is less likely to develop secondary 
failure than is one who is under 
fair control. Patients who required 
large doses of insulin have more 
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secondary failures than do those 
who require no insulin. The longer 
the duration of diabetes, the greater 
is the incidence of secondary fail-
ure. The true incidence of second-
ary failure is probably about 0.25% 
during each month of treatment 
with a sulfonylurea. The exact rate 
makes little difference, as long as 
physicians are aware that this con-
dition can occur at any time. 
CONTRAINDICATIONS TO 
SULFONYLUREAS 
When they were first introduced, 
the sulfonylureas were not recom-
mended for patients with infection, 
surgery, pregnancy, or neuropathy. 
These precautions are still included 
on the package inserts. However, 
many patients have successfully un-
dergone major surgical procedures 
while taking these drugs. Excellent 
diabetic control was maintained in 
the post-operative period, but a few 
patients required supplemental in-
jections of insulin for two or three 
days. In the presence of infection, 
the insulin requirements rise and 
supplemental insulin may be needed 
until inflammation has subsided. In 
a group of 20 pregnant patients 
treated with oral drugs, there was 
no evidence of any deleterious ef-
fect that could be attributed to the 
drugs, even though there were only 
13 live babies in the group. 
Many physicians have used the 
sulfonylurea drugs in patients with 
very mild diabetes. Theoretically, if 
hypertrophy and hyperplasia of the 
,8-cells is produced, the eventual 
use of insulin could be postponed. 
However, sufficient data to substan-
tiate this is not yet available. Pa-
tients with minimal diabetes are 
more responsive to the sulfonylurea 
drugs, and may easily develop hy-
poglycemia. There is little justifica-
tion for the use of any drug in pa-
tients who have a normal fasting 
blood sugar, even though the post-
prandial blood sugar is elevated. 
PHENFORMIN 
Phenformin (DBI) is a different 
type of chemical that acts on mus-
cle and liver cells in an undeter-
mined manner to increase glucose 
uptake. This drug will lower the 
blood sugar of any diabetic if a 
large enough dose is given, but it 
does not lower the blood sugar of 
non-diabetics. It is effective in many 
patients who do not respond to a 
sulfonylurea. It is also used to in-
crease the effectiveness of both sul-
fonylureas and insulin. 
Obese patients taking phenformin 
usually lose one pound each month. 
Because no other method of treat-
ing diabetes causes such consistent 
weight loss, this is the preferable 
drug for obese diabetics. The aver-
age therapeutic dose is slightly less 
than 1 mg per lb of body weight, 
but there is a narrow therapeutic 
margin. If the dose is raised too 
high in an effort to produce an-
orexia, the patient may interpret 
nausea as hunger and overeat. 
When an excessive dose is given, 
any patient will develop such side 
effects as metallic taste, foul breath, 
anorexia, vomiting, diarrhea, ab-
dominal cramps, and malaise. 
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These side effects are readily con-
trolled by stopping the drug, or 
reducing the dose. The incidence of 
side effects is less with the use of 
the time dispersal (TD) capsules 
than it is with the tablets. Severe 
side effects are now rare, and true 
toxic effects are of little conse-
quence. The tablets have a four-
hour duration of action and are 
usually given three to four times 
daily. The TD capsules have a 
longer (12 hours) effect, and are 
usually given at breakfast and sup-
per. 
There have been reports of lactic 
acidosis in patients taking large 
doses of phenformin. These pa-
tients usually had hepatic, renal, or 
severe cardiac disease with shock 
and tissue hypoxia. They were seen 
only after symptoms of toxicity 
had been present for several days. 
In our experience lactic acidosis 
has not been a problem. It is es-
sential that all diabetic patients be 
followed closely regardless of the 
method of treatment used. 
COMBINED USE OF ORAL 
HYPOGLYCEMIC DRUGS 
There are some patients who im-
prove but do not attain good con-
trol with a sulfonylurea drug with 
phenformin alone, but who achieve 
satisfactory diabetic control on both 
drugs together. The average dose 
for the combination is 500 mg of 
chlorpropamide and 150 mg of 
phenformin each day, but the dose 
of either drug must be varied in 
order to produce the desired con-
trol in each patient. 
INSULIN PLUS PHENFORMIN 
There have been reports stating 
that brittle diabetics can be stabi-
lized if they are given one of the 
oral drugs in addition to insulin. 
In our study using tolbutamide 
with insulin, and then a placebo 
with insulin, there was no differ-
ence between the two groups. Most · 
diabetics are made unstable by 
physicians who prescribe too much 
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insulin, resulting in hypoglycemia 
and rebound hyperglycemia. When 
the insulin dose is reduced, there is 
less hypoglycemia and consequently 
less rebound hyperglycemia. If the 
patient is given another drug at 
the same time the insulin dose is 
reduced, the new drug is credited 
with the improvement actually 
produced by the insulin reduction. 
Some authors who have reported 
good results with this combination 
have not used placebo controls. 
The combination of insulin plus a 
sulfonylurea is worthless, but the 
supplemental use of insulin in pa-
tients taking a sulfonylurea is help-
ful during transient stress. 
The combination of insulin and 
phenformin has been widely advo-
cated to stabilize brittle diabetics. 
In our study only 2 out of 37 pa-
tients on this regimen showed im-
provement. The other 35 were no 
better controlled than they were on 
insulin plus a placebo. The two pa-
tients whose control improved pos-
sibly ate less because of the mild 
anorexia produced by phenformin. 
Patients who need insulin usually 
do best when they are given nothing 
but insulin. 
Following the introduction of 
oral drugs, the fear was expressed 
that the simplified treatment would 
result in an epidemic of degenera-
tive complications. This fear has not 
been borne out, and as long as satis-
factory control is achieved, there 
is probably no contraindication to 
the use of oral hypoglycemic drugs. 
CONCLUSION 
The sulfonylurea drugs stimulate 
the pancreas to produce more in-
sulin and are effective in patients 
with mild diabetes. Because it is 
excreted more slowly, chlorpropa-
mide is four times more potent, and 
acetohexamide twice as potent, as 
tolbutamide. Chlorpropamide gives 
the most effective and most eco-
nomical diabetic control. Phen-
formin increases the use of glucose 
in the muscle cells and is effective 
in many patients who do not re-
spond to the sulfonylurea drugs. 
The average dose of phenformin is 
slightly less than 1 mg per lb body 
weight. If excessive phenformin is 
given, the patient will develop re-
versible gastrointestinal side effects. 
Phenformin is the only drug as-
sociated with consistent weight loss, 
and therefore is the drug of choice 
in the obese diabetic. Continued use 
of phenformin and chlorpropamide 
is effective in many patients who 
do not achieve satisfactory control 
with either drug alone. A combina-
tion of sulfonylurea and insulin is 
worthless, and a combination of 
phenformin and insulin is rarely 
valuable. Surgery, pregnancy, in-
fection, or degenerative complica-
tions are not absolute contraindica'-
tions to oral drugs, as long as the 
diabetes is well controlled. There 
is no evidence of increased inci-
dence of degenerative complications 
in patients controlled by oral hy-
poglycemic drugs. 
